Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 26;5(5):e564. doi: 10.1097/HS9.0000000000000564

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

PMC Copyright notice

Figure 4. — Timeline of plasma biomarkers that change during ibrutinib treatment. (A) Timeline for CCL proteins, CXCL proteins, ILs, IL-Rs, TNFSF, and TNFRSF members. (B) Timeline for CD molecules. Plasma biomarkers expressed by B cells are listed in green. Statistically significant changes in the plasma levels between the respective time points and pretreatment are depicted as a dark blue (decrease) or dark red (increase) bar with a thick arrow. Trends are depicted as a light blue (decreasing tendency) or light red (increasing tendency) bar with a thin arrow. CCL = chemokine ligand; CXCL12 = C-X-C motif chemokine ligand 12.